Angiotensin-converting Enzyme (ACE) Inhibitor

ACE Rat Pre-designed siRNA Set A contains three designed siRNAs for ACE gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Spirapril is a potent and cross the blood-brain barrier angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure.

REV 5975 is a angiotensin converting enzyme (ACE) inhibitor. REV 5975 shows a partial reduction of the angiotensin I effect.

Quinaprilat hydrate is a non-mercapto Angiotensin Converting Enzyme (ACE) inhibitor, the active metabolite of Quinapril. Quinaprilat hydrate specifically blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II and inhibits the degradation of bradykinin. Quinaprilat hydrate acts as anti-hypertensive agent and vasodilator.

Phe-Tyr is an ACE inhibitor. Phe-Tyr can be isolated from wakame. Phe-Tyr exhibits mild concentration-dependent toxicity to fibroblasts. Phe-Tyr can be used in studies related to hypertension and cardiovascular diseases.

Zabicipril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Zabicipril can be used for the study of blood pressure and peripheral arterial insufficiency.

IRW is an orally active tripeptide produced from egg white with angiotensin converting enzyme (ACE) inhibitory properties. IRW can prevent high-fat diet (HFD)-induced Non-alcoholic fatty liver disease (NAFLD) by modulating hepatic lipid metabolism and increasing mitochondrial content. IRW decreases hepatic triglyceride content and lipid droplet size. IRW increases the hepatic mitochondrial complexes and citrate synthase activity, phosphorylation of 5’-AMP-activated protein kinase and microsomal triglyceride transfer protein abundance. IRW increases phosphorylated acetyl CoA carboxylase and mitochondrial complexes, IRW can be used for the research of inflammation.

ASF-006 sodium, a tetrapodal tryptophan derivative, is a potent viral invasion inhibitor. ASF-006 sodium shows potent antiviral activity against different SARS-CoV-2 Omicron variants but not against the ancestral SARS-CoV.2 strain (Wuhan-Hu-1). ASF-006 sodium competitively inhibits receptor-binding domain (RBD)-ACE2 binding via an allosteric mechanism. ASF-006 sodium inhibits Omicron BA.1, Omicron XBB.1.5, respiratory syncytial virus (RSV) and Ebola virus infection with IC₅₀s of 0.02 μM, 0.3 μM, 1.52 μM and 0.2 μM, respectively. ASF-006 sodium inhibits cell entry of both HIV and enterovirus A71[1].

Benazepril-d₅ hydrochloride is deuterium labeled Benazepril hydrochloride. Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy.

LADW is a tetrapeptide derived from the hydrolysate of tuna skeletal muscle myosin, with dual inhibitory activities against angiotensin-converting enzyme 1 (ACE1) and α-glucosidase. The IC₅₀ value of LADW against ACE1 is 28.02 μM, while its IC₅₀ value against Saccharomyces cerevisiae α-glucosidase is 4.40 mM. LADW binds competitively to the active site of ACE1, stabilizes the enzyme conformation, and blocks substrate binding. LADW binds to α-glucosidase to inhibit carbohydrate hydrolysis and can also alter starch structure. LADW can be used in studies related to hypertension and diabetes.

Delapril (CV-3317) is an orally active angiotensin I converting enzyme (ACE) inhibitor. Delapril has antihypertensive activity.

GW 796406 is a novel vascular peptidase inhibitor. GW 796406’s inhibitory activity against NEP (IC₅₀ ≈ 1.1-2.5 nM) is about three times that of ACE (IC₅₀ ≈ 1.6-4.7 nM). GW 796406 can be used for research on cardiovascular conditions.

Indolapril hydrochloride (CI-907) is an orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor. Indolapril hydrochloride is highly specific in suppressing the contractile or pressor responses to Angiotensin I. Indolapril hydrochloride is a potent antihypertensive agent.

Enalapril sodium (MK-421 sodium) is an orally active angiotensin-converting enzyme inhibitor. Enalapril sodium blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril sodium inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril sodium attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril sodium reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril sodium is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology.

RXP 407 is a potent and selective Angiotensin-converting Enzyme (ACE) inhibitor with a K_i of 12nM.

Acein-1 is an angiotensin-converting enzyme (ACE) inhibitor with an IC₅₀ of 16 μM against rabbit lung ACE. Acein-1 does not bind to the catalytic site of ACE and cannot be hydrolyzed by ACE. Acein-1 can be used in the research of hypertension.

SARS-CoV-2-IN-113 (Compound 24) is a sulfonohydrazide derivative against SARS-CoV-2 infection with an IC₅₀ of 8.320 μM. SARS-CoV-2-IN-113 exerts potent antiviral effects by inhibiting the entry and replication of SARS-CoV-2, and downregulating the expression of genes and proteins such as Spike, ACE-2, and RdRp. SARS-CoV-2-IN-113 has high selectivity and low cytotoxicity, and can be used in the research of SARS-CoV-2.

YYLLVR is an angiotensin-converting enzyme (ACE) inhibitory peptide with an inhibitory rate of 89.10%. YYLLVR has a lower binding energy for ACE of -35.98 kcal/mol. YYLLVR can be used in the study of hypertensive diseases.

(Z)-Guggulsterone (Standard) is the analytical standard of (Z)-Guggulsterone. This product is intended for research and analytical applications. (Z)-Guggulsterone, a constituent of Indian Ayurvedic medicinal plant Commiphora mukul, inhibits the growth of human prostate cancer cells by causing apoptosis. (Z)-Guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling axis. (Z)-Guggulsterone is also a potent FXR antagonist. (Z)-Guggulsterone reduces ACE2 expression and SARS-CoV-2 infection.

RB-105 is an inhibitor of angiotensin-converting enzyme (ACE) (K_i = 4.2 nM) and neutral endopeptidase (NEP) (K_i = 1.7 nM). RB-105 after inhibiting ACE reduces the production of Ang II and increase the level of bradykinin. RB-105 after inhibiting NEP increases the level of natriuretic peptide and further increases the level of bradykinin, thereby generating a powerful synergistic effect. RB-105 has significant antihypertensive and natriuretic effects in both spontaneously hypertensive rats and normal blood pressure rats. RB-105 can be used for research on hypertension.